Bone Biologics Corp (BBLG) FinancialsBBLGFinancialBone Biologics Corp

Evaluating the bottom line, Bone Biologics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -54.96%, provide a clear picture of how effectively BBLG converts its operational activities into shareholder value.

In the context of the broader market, BBLG competes directly with industry leaders such as AEMD and VBIO. With a market capitalization of $1.19M, it holds a significant position in the sector. When comparing efficiency, BBLG's gross margin of N/A stands against AEMD's N/A and VBIO's N/A. Such benchmarking helps identify whether Bone Biologics Corp is trading at a premium or discount relative to its financial performance.

Bone Biologics has consistently reported negative net income, with losses reaching -4153506 USD in Q3 2024. The company's EPS has also been negative, with a value of -14.21 in Q3 2024, indicating ongoing financial struggles.